RECURSION PHARMACEUTICALS, INC. (RXRX): Results of Operations and Financial Condition
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program • Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursi
How this was made
The 30-second read
Why it matters
The most tradable elements are (1) the Genentech neuroscience validated target option exercised and advanced into an early discovery program, (2) specific pipeline timing updates for REC-7735 (IND cleared, Phase 1/2 start in 2H26), and (3) a concrete reduction in 2026 cash operating expense guidance to <$375 million.
Market read
Traders can reassess Recursion’s platform credibility and cash runway assumptions ahead of the scheduled earnings call, using the validated target milestone and the guidance reduction as fresh inputs.
What to watch
Investors may focus on whether the FDA registrational path update for REC-4881 in 2H26 changes probability-weighted timelines, and on how much of the collaboration milestone value is contingent on future program starts.
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Revenue was $7.7 million versus $19.2 million in the prior-year quarter, while research and development expenses decreased to $89.6 million from $128.6 million and 2026 cash operating expense guidance was reduced to <$375 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $7.7 million | – | – |
| Research and development expensesGAAP | $89.6 million | – | – |
| Cash, cash equivalents and restricted cashother | $556.8 million | – | – |
| Roche and Genentech collaboration upfront and milestone payments to dateother | $216 million | – | – |
| Sanofi collaboration upfront and milestone payments to dateother | $134 million | – | – |
2026 outlook
- Operating expenses<$375 million
- NoteBased on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028.
What drove it
- Roche and Genentech revenue recognized was less in the current period due to the successful completion of certain project phases in the prior period.
- Research and development expenses decreased primarily due to lower platform costs resulting from the timing of Tempus record purchases.
- Genentech exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target into a small molecule early discovery program.
- REC-7735 was precision designed to show >100-fold selectivity for the H1047R mutant over wild type.
- The REC-7735 development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion's AI-native design platform.
- Agent-supported enrollment strategies contributed to a 1.3 to 1.6x increase in enrollment rates versus historical benchmarks.
Concerns
- Total revenue was $7.7 million for the second quarter of 2026, compared to $19.2 million for the second quarter of 2025.
- Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026 compared to $753.9 million as of December 31, 2025.
- The supplied filing text ends during the explanation of research and development expenses, before the complete financial-results disclosure and financial statements.
What to watch
- An update to define the registrational path for REC-4881 is expected in 2H26.
- Additional Phase 2 safety and efficacy data from the TUPELO clinical trial will be presented in November 2026.
- The Phase 1/2 ZINNIA clinical study for REC-7735 is expected to be initiated in the second half of 2026.
- Additional Phase 1 dose escalation data for REC-1245 are expected in 2H26.
- Potential differentiated AI-enabled oral molecules could reach development candidate and late-stage discovery milestones with Sanofi over the next 6-12 months.
Balance sheet and cash flow
- Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026 compared to $753.9 million as of December 31, 2025.
- Based on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028.
Analysis
Second-quarter revenue was $7.7 million, compared to $19.2 million in the second quarter of 2025. The company attributed lower Roche and Genentech revenue recognition to successful completion of certain project phases in the prior period. The result underscores that reported collaboration revenue can vary with the timing of project milestones and completion phases.
Research and development expenses decreased to $89.6 million from $128.6 million. Recursion cited lower platform costs resulting from the timing of Tempus record purchases as a primary driver. The company also reduced 2026 cash operating expense guidance to <$375 million from <$390 million, placing expense control alongside continued pipeline development.
Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026, compared with $753.9 million as of December 31, 2025. Management stated that, based on current operating plans with no additional financing, its cash runway is expected to extend into early 2028. No operating cash flow, free cash flow, debt, repurchase, or dividend data were included in the supplied text.
Operationally, Genentech exercised the first Validated Target Option in the neuroscience collaboration and advanced a previously unexplored target into a small molecule early discovery program. Recursion also reported an IND clearance for REC-7735 and expects to initiate its Phase 1/2 ZINNIA study in the second half of 2026. Near-term execution points include the expected REC-4881 registrational-path update in 2H26, additional REC-4881 Phase 2 data in November 2026, REC-7735 trial initiation, and additional REC-1245 Phase 1 data in 2H26.
Management, verbatim
Recursion has reached a pivotal point where our AI-native platform is translating unique data into potential first-in-class therapeutic opportunities.
Najat Khan, Ph.D., Chief Executive Officer of Recursion
Not in the filing
stated, not guessed- Gross profit and gross margin
- Selling, general and administrative expenses
- Total operating expenses
- GAAP operating income or loss
- Non-GAAP operating income or loss
- GAAP net income or loss
- Non-GAAP net income or loss
- GAAP earnings or loss per share
- Non-GAAP earnings or loss per share
- Weighted-average shares outstanding
- Operating cash flow
- Free cash flow
- Debt balances
- Share repurchases
- Dividends
- Revenue, gross margin, tax rate, and other financial guidance beyond 2026 cash operating expense guidance
- Prior outlook document for guidance comparison
- Complete remaining financial-results disclosure, as the supplied filing text ends mid-sentence
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K (Item 2.02) accompanies Recursion’s Q2 2026 financial results and business updates, including collaboration progress with Genentech and Roche and pipeline/IND and trial timing updates.
Ticker impact
Recursion reported Q2 results and said Genentech advanced the first validated neuroscience target into an early discovery program, plus updated 2026 cash opex guidance.
Moderate upside bias into the earnings call as investors price in platform proof points and lower 2026 cash operating expense.
The filing is a fresh 8-K with new collaboration milestone (validated target option exercised) and a specific guidance cut, both actionable for biotech risk/reward. However, it is not a late-stage clinical readout or regulatory decision, limiting magnitude.
Market effects
Supports the broader TechBio narrative that AI-native platforms can generate and experimentally validate novel targets, potentially improving sentiment toward similar discovery-model companies.
Limited, as the disclosure is company-specific and not a macro/regional policy event.
Collaboration milestones with Roche and Genentech reinforce international pharma-techbio partnerships, but without a global regulatory or approval catalyst.
Counterpoint
The guidance cut may reflect burn management rather than accelerating value creation, and early discovery progress may not translate into near-term clinical catalysts.
Key entities
- companyRecursion Pharmaceuticals, Inc.
Nasdaq-listed TechBio company reporting Q2 results, collaboration milestones, and updated 2026 cash operating expense guidance.
- partnerGenentech
Exercised the first validated target option and advanced a neuroscience target into an early discovery program with Recursion.
- partnerSanofi
Partnered collaboration referenced for I&I and oncology portfolio progress and potential milestones.
- pipeline_assetREC-4881
MEK1/2 inhibitor in FAP with updates on trial enrollment and planned FDA registrational path update in 2H26.
- pipeline_assetREC-7735
PI3Kα H1047R inhibitor with IND cleared and Phase 1/2 start expected in 2H26.
